Pediatric-onset CD patients | Low BMD | Normal BMD | p-value |
---|---|---|---|
Z-score<−1 | Z-score ≥−1 | ||
n=77 | n=46 | n=31 | |
% | 60% | 40% | |
NOD2 variant n (%) | 24 (52%) | 10 (32%) | p=0.10 |
One variant allele | 17 | 5 | p=0.061 |
Two variant alleles | 7 | 5 | p=0.75 |
Homozygous variant alleles | 7 | 0 | p=0.037* |
Gender: female/male in % | 45/55 | 48/52 | p=0.89 |
Age: y | |||
mean/SD | 25/12.8 | 24/13.9 | p=0.62 |
median/interquartile range | 21/17-30 | 19/15-29 | p=0.29 |
average disease duration/SD | 12.2/11.6 | 11.6/10.8 | p=0.84 |
Age at diagnosis: y | |||
mean/SD | 13/3.6 | 12/5.1 | p=0.33 |
median/interquartile range | 14/11-16 | 13/10-17 | p=0.69 |
Localization: n (%) | |||
L1 ileal | 8 (17%) | 9 (29%) | p=0.27 |
L2 colonic | 8 (17%) | 6 (19%) | p=1.0 |
L3 ileocolonic | 30 (65%) | 16 (52%) | p=0.25 |
L4 isolated upper disease | 0 (0%) | 0 (0%) | p=1.0 |
Upper GI involvement | 15 (33%) | 13 (42%) | p=0.47 |
Behaviour: n (%) | |||
B1 non-stricturing/penetrating | 27 (59%) | 20 (65%) | p=0.64 |
B2 stricturing | 11 (23%) | 6 (19%) | p=0.78 |
B3 penetrating intern | 6 (13%) | 3 (10%) | p=0.73 |
B3p penetrating perianal | 9 (19%) | 3 (10%) | p=0.34 |
Underweight at diagnosis | 14/27 (52%) | 5/22 (32%) | p=0.0453* |
Underweight in 1y follow-up | 14 (30%) | 2 (6%) | p=0.0113* |
Short stature | 5 (11%) | 1 (3%) | p=0.39 |
Treatment: n (%) | |||
Steroid dependent/refractory | 23 (50%) | 9 (29%) | p=0.10 |
Azathioprine / MTX | 35 (76%) | 15 (48%) | p=0.016* |
Anti-TNFα-antibody | 20 (44%) | 7 (26%) | p=0.09 |